Microbiological safety of a novel bio-artificial liver support system based on porcine hepatocytes: a experimental study by Bing Han et al.
Han et al. European Journal of Medical Research 2012, 17:13
EUROPEAN JOURNAL 
OF MEDICAL RESEARCH
http://www.eurjmedres.com/content/17/1/13RESEARCH Open AccessMicrobiological safety of a novel bio-artificial liver
support system based on porcine hepatocytes: a
experimental study
Bing Han1,2†, Xiao-lei Shi1,2†, Yue Zhang2,1, Xue-hui Chu1,2, Jin-yang Gu1,2, Jiang-qiang Xiao1, Hao-zhen Ren1,
Jia-jun Tan1, Zhong-ze Gu3 and Yi-tao Ding1,2*Abstract
Background: Our institute has developed a novel bio-artificial liver (BAL) support system, based on a multi-layer
radial-flow bioreactor carrying porcine hepatocytes and mesenchymal stem cells. It has been shown that porcine
hepatocytes are capable of carrying infectious porcine endogenous retroviruses (PERVs) into human cells, thus the
microbiological safety of any such system must be confirmed before clinical trials can be performed. In this study,
we focused on assessing the status of PERV infection in beagles treated with the novel BAL.
Methods: Five normal beagles were treated with the novel BAL for 6 hours. The study was conducted for
6 months, during which plasma was collected from the BAL and whole blood from the beagles at regular intervals.
DNA and RNA in both the collected peripheral blood mononuclear cells (PBMCs) and plasma samples were
extracted for conventional PCR and reverse transcriptase (RT)-PCR with PERV-specific primers and the porcine-
specific primer Sus scrofa cytochrome B. Meanwhile, the RT activity and the in vitro infectivity of the plasma were
measured.
Results: Positive PERV RNA and RT activity were detected only in the plasma samples taken from the third circuit of
the BAL system. All other samples including PBMCs and other plasma samples were negative for PERV RNA, PERV
DNA, and RT activity. In the in vitro infection experiment, no infection was found in HEK293 cells treated with
plasma.
Conclusions: No infective PERV was detected in the experimental animals, thus the novel BAL had a reliable
microbiological safety profile.
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Mesenchymal stem cellsBackground
Acute liver failure (ALF) is a serious clinical disease with
high mortality rate. Although liver transplantation is cur-
rently recognized as the most effective treatment for
ALF, its application has been seriously limited by the lack
of donor organs, the high cost of treatment, and the* Correspondence: yitaoding@hotmail.com
†Equal contributors
1Department of Hepatobiliary Surgery, the Affiliated DrumTower Hospital of
Nanjing University Medical School, Number 321 Zhongshan Road, Nanjing
210008, China
2Department of Hepatobiliary Surgery, DrumTower Clinical Medical College
of Nanjing Medical University, Number 321 Zhongshan Road, Nanjing
210008, China
Full list of author information is available at the end of the article
© 2012 Han et al; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orrequirement for life-long immunosuppressive therapy
[1,2]. Therefore, bio-artificial liver (BAL) support sys-
tems, based on functional hepatocytes, have received ex-
tensive attention because of their unique biological
function, and considerable progress has been made in
their development [3-5]. Currently, porcine hepatocytes
are still the main cell sources for such systems because
of their adequate resources, accessibility, and features
similar to human hepatocytes [6-8]. However, because
they are xenogeneic cells, porcine hepatocytes are asso-
ciated with a number of problems, including that of
microbiological safety. Porcine endogenous retrovirus
(PERV) was first discovered in 1971 in porcine kidney. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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first time that PERV released from PK15 could infect
human embryonic kidney (HEK)293 cells in vitro [10].
Subsequently, PERV-A and PERV-B were confirmed as
the human-tropic subtypes [11]. It was later found that
PERV could successfully infect a variety of human cells
in vitro, including endothelial cells, fibroblasts and bone
marrow stromal cells, and virus replication was seen in
some of these cells. Two other in vivo studies showed
that implanted porcine islets could result in PERV infec-
tion in non-obese diabetic/severe combined immuno-
deficiency (NOD/SCID) mice [12]. Thus, transmission of
PERV is a microbiological safety issue that cannot be
ignored in BAL systems using porcine hepatocytes.
We developed a novel multi-layer radial-flow bioreac-
tor containing galactosylated chitosan nanofiber scaf-
folds, which we found to have a high level o fefficiency
in vitro [13]. The bioreactor is composed of a stack of
65-layer round flat plates and a cylindrical container with
an inlet on the top and an outlet on the bottom. A co-
culture system of porcine hepatocytes and mesenchymal
stem cells (MSCs), which had been established previ-
ously in our institute [14], was perfused into the bioreac-
tor to act as functional cells, and a new extracorporeal
BAL support system based on the novel multi-layer ra-
dial-flow bioreactor and the co-culture system of porcine
hepatocytes and MSCs. was constructed. This study is a
preclinical experiment identifying the microbiological
safety of the novel BAL. In this study, we used five nor-
mal dogs to assess transmission of PERV. The aim of this
research was to investigate whether there was a possibil-
ity of transmission of PERV into the experimental dogs
using this new BAL support system.
Methods
Animals and reagents
All animal procedures were performed in accordance with
institutional and national guidelines and with the approval
by the Animal Care Ethics Committee of Nanjing Univer-
sity and Nanjing Drum Tower Hospital.
Five outbred white pigs with an average weight of 15–
20 kg and five inbred beagles with an average weight of
11–13 kg were used for the experiments.
All cell culture-related reagents were purchased from
Gibco (Grand island, N.Y.USA).
Establishing co-culture system of porcine hepatocytes and
mesenchymal stem cells
A co-culture system of porcine hepatocytes and MSCs was
prepared as described previously [14]. In brief, bone mar-
row was aspirated from the iliac crest of the pigs, then the
mononuclear cells were collected over a Ficoll histopaque
layer by gradient centrifugation (20 minutes, 400 g, density
1.077 g/ml) and seeded at a density of 1 × 106 cells/cm2 ingrowth medium containing low-glucose DMEM supple-
mented with 10% FBS, 100 IU/ml penicillin and 100 mg/
ml streptomycin. The culture medium was replaced after
the first 24 hours, and the subculture was prepared accord-
ing to standard cell-culture techniques. The cultured cells
were confirmed as MSCs by analysis (FACScan; Becton
Dickinson, San Jose, CA, USA) of surface markers, includ-
ing CD45, CD29, CD44, and CD90. The primary pig hepa-
tocytes were harvested using a two-step in situ collagenase
perfusion technique. The viability of the isolated primary
hepatocytes, as determined by trypan blue exclusion, was
greater than 95%. Non-parenchymal cells were identified
based on size (<10 μm in diameter) and morphology (non-
polygonal or stellate), and made up less than 1% of cells,
which was confirmed by immunocytochemical analysis of
albumin and cytokeratin 18. The mixed suspension of fresh
hepatocytes and MSCs during passages 3 to 5 (2:1) was
perfused at a density of 106 cells/ml into a substratum of
500 ml RPMI-1640 without sera, and incubated in our new
bioreactor at 37°C and 5% CO2.
Construction and application of the new bio-artificial liver
support system
The new BAL support system consisted of three roller
pumps, a heparin pump, an infusion heater, a plasma fil-
ter (Sorin Group Italia, Mirandola, Italy), a plasma com-
ponent separator (Kawasumi Laboratories Inc, Tokyo,
Japan) serving as immunoprotective barrier, an oxygen-
ation device, and a multi-layer radial-flow bioreactor
containing galactosylated chitosan nanofiber scaffolds.
The bioreactor and the oxygenation device was prepared
and kept in an incubator with am internal temperature
of 37°C as previously reported [13]. The whole system
was then assembled as shown in Figure 1.
Catheters were inserted into the internal carotid artery
and internal jugular vein of the dogs under continued
anesthesia by intravenous administration of propofol
(Diprivan; Astrazeneca, Wuxi, China) at a dose of
10 mg/kg/h, and the catheters were then connected to
the BAL device (Figure 1). The BAL treatment was
begun 4 hours after the cells were seeded, when most
cells were adhered to the galactosylated chitosan nanofi-
ber scaffolds. During the first circuit, the whole blood in
was perfused at a rate of 40 ml/min for 6 hours, then
during the second circuit, the plasma was separated from
the plasma filter at a rate of 15 ml/min, and finally dur-
ing the third circuit, the plasma was filtered through the
plasma component separator at a rate of 15 ml/min.
Heparin (100U/kg) was administered intravenously to
the dogs at the start of treatment and continued at a
dose of 40 U/kg/h into the first circuit, and removed 30
minutes before the end of the treatment. Samples of the
plasma circulating in the BAL system and samples of
whole blood from the beagles were collected at regular
Figure 1 Construction of the bio-artificial liver support system. The system consists of three roller pumps, a heparin pump, an infusion
heater, a plasmafilter, a plasma component separator, an oxygenation device, and a multi-layer radial-flow bioreactor containing galactosylated
chitosan nanofiber scaffolds. The bioreactor and the oxygenation device is kept in an incubator with the internal temperature of 37°C. All devices
are connected by sterile tubing. The dotted arrow indicates where the samples were drawn into the circuits.
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treatment, and at 12 hours, 1, 3, 5 and 7 days, 2, 3, and
4 weeks, and 3 and 6 months after treatment) until the
research was completed 6 months after the treatment.
Complete blood count (CBC) was assessed for each
blood sample. PBMCs and plasma were separated from
the whole blood, and frozen at −80°C for later use.
DNA extraction and PCR
Total DNA was extracted from the plasma and the sepa-
rated PBMCs by means of a DNA extraction kit (Axygen
Scientific Inc.,Union City, CA, USA) in accordance with
the manufacturer’s instructions, using the primers shown
in Table 1 [15,16]. PCR conditions were 50°C for 30 min-
utes, then 95°C for 5 minutes, followed by 35 cycles of
94°C for 30 seconds, 55°C for 45 seconds, 72°C for 30
seconds, with a final extension step of 72°C for 5 min-
utes. Samples were separated by gel electrophoresis in
2% agarose gels and stained with ethidium bromide.
DNA and RNA extracted from PK15 cells was used as
positive control and pure water as negative control.
RNA extraction and reverse transcriptase PCR
Total RNA was extracted from the PBMCs and the
plasma with Trizol reagent (Invitrogen Inc., Carlsbad,
USA), and dissolved in diethyl pyrocarbonate-treated
water in accordance with the manufacturer’s instruc-
tions. The extracted RNAs had an OD 260/280 of 1.60
and 2.00, respectively. DNAs were reverse-transcribed to
cDNA using commercial kits (Biouniquer Technology
Co.,Ltd, Hongzhou, China) in accordance with the man-
ufacturer’s instructions, then PCR was performed as
described above.
Reverse transcriptase activity assay
The RT activity of the plasma was assessed using a com-
mercial kit (C-type RT activity Kit; Cavidi-Tech, Uppsala,Sweden), in accordance with the manufacturer’s
instructions.Exposure of canine peripheral blood mononuclear cells to
porcine endogenous retrovirus
PERV was harvested from the supernatant of PK15 cells
and concentrated by sucrose density-gradient centrifuga-
tion [17]. Canine PBMCs isolated from the blood of nor-
mal dogs were exposed to PERV in a culture medium
composed of 1 ml PERV and 4 ml of high-glucose
DMEM with 0.8 g/ml polybrene (hexadimethrine brom-
ide; Sigma Aldrich) for 24 hours. The cells were then
washed with PBS twice, and subcultured for 1 month. Fi-
nally, the cells were collected for assessment of PERV by
PCR, RT-PCR and RT activity assay. Previously. The
infected cells were used as a positive control.In vitro infection experiments
The in vitro infection experiments were performed as
described previously [18], with some modifications HEK-
293 cells (gift from Professor Hua, Nanjing University)
were passaged overnight in 25-ml tissue culture flasks
and then incubated in a culture composed of 2 ml of
separated plasma harvested at defined times, and 3 ml of
DMEM-HG with 0.8 g/ml polybrene. Meanwhile, the
supernatant of PK15 cells and 0.8 g/ml polybrene was
inoculated into the culture of HEK293 cells as a positive
control. After 4 hours of exposure at 37°C, the inoculum
was removed, and the cell monolayer was washed twice
with PBS. The cells were then cultured with high-glucose
DMEM supplemented with 10% FBS, and passaged to
confluence for 1 month before collection. The collected
HEK293 cells were tested for PERV DNA by PCR. RT ac-
tivity was measured in the supernatant of treated
HEK293 cells.
Table 1 Primers used for PCR









SsCytB, Sus scrofa cytochrome B.
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Status of animals receiving bio-artificial liver treatment
Animals had their heart and respiratory rates monitored
continuously by an electrocardiography, and these were
stable during the extracorporeal perfusion. All dogs were
able to stand and take food within 12 hours from the
end of the treatment., and their biological behavior
recovered to the pre-treatment state within 72 hours. All
animals survived throughout the entire 6-month study.Complete blood count
The results of the CBC are listed in Table 2.Detection of porcine endogenous retrovirus DNA and
RNA in peripheral blood mononuclear cells
The agarose gel electrophoresis results showed that there
was no PERV DNA or RNA in the dog PBMCs collected
at various times. Screening for the porcine-specific gene
SsCytB did not find this gen in the DNA of the PBMCs of
any of the five dogs (Figure 2).Detection of porcine endogenous retrovirus DNA and
RNA in plasma
Except for positive bands representing the protease and
polymerase gene in circuit 3 before and during treatment,
all results of RT-PCR with the RNA from collected plasma
were negative (Figure 3). The same results were obtained
for plasma DNA, and no SsCytB sequence was seen in the
plasma.Table 2 Complete blood count of dogs with bio-artificial liver
Time points White blood cells, × 109/l
Before treatment 13.0 ± 4.72
After 3 hours of treatment 9.2 ± 9.56
6 h during treatment 33.7 ± 6.20
1 day after treatment 29.4 ± 12.16
3 day after treatment 17.9 ± 8.04
7 day after treatment 17.3 ± 5.36Reverse transcriptase activity assay
The RT activity was examined twice for all collected
plasma samples. The results showed that the RT activity
was limited to the plasma in the third circuit before and
at 3 hours of treatment. RT activity was not detected in
any the other samples including all dog plasma collected
during and after the treatment (Table 3).
Infection of HEK293 cells in vitro
Results were negative for PERV-specific genes including
protease and polymerase genes and the porcine-specific
SsCytB sequence in the DNA from HEK293 cells inocu-
lated with collected plasma. DNA extracted from PK15-
infected HEK293 cells and the pure water was used as
positive control and negative control, respectively. All
supernatants from treated HEK293 cells were negative
for RT activity.
Discussion
We report the development of a novel BAL system based
on a new multi-layer radial-flow bioreactor containing
galactosylated chitosan nanofiber scaffolds and a co-sys-
tem of porcine hepatocytes and MSCs. This was developed
in our institute because clinical trials of other BAL systems
have shown disappointing results [3,4]. To improve the
cellular function, each plate was covered with nanofiber
scaffolds to mimic the topography of extracellular matrix
(ECM), and the galactose was grafted onto the nanofibers
to mimic the biochemical environment of ECM [13]. We
used a co-culture system of porcine hepatocytes and MSCs
at a ratio of 2:1, which was introduced into the BAL sys-
tem [14]. Both of these two elements have been shown to
have better hepatoctye-specific function in vitro, so we
expected our BAL to be superior to previous devices. A
plasma component separator was placed between circuits
2 and 3 to allow with media exchange by passive diffusion
across the semipermeable membrane inside, as with other
BAL systems [4].
PERV is known to exist generally in the porcine gen-
ome. Various porcine cells can excrete PERV particu-
lates, which have been shown to infect a variety of
human cells in vitro [12], and a transient PERV infection
in guinea pigs was seen in vivo [19]. Previous reportstreatment
Red blood cells, × 1012/l Platelets, × 1012/l
5.6 ± 1.27 252.1 ± 100.22
6.9 ± 1.44 159.9 ± 106.28
7.2 ± 0.76 244.0 ± 76.47
7.2 ± 0.98 229.72 ± 99.63
5.6 ± 1.16 205.3 ± 161.58
4.6 ± 1.18 214.3 ± 159.55
Figure 2 Representative results of PCR electrophoresis with the
DNA of beagle peripheral blood mononuclear cells (PBMCs). No
PERV DNA or Sus scrofa cytochrome B (SsCytB) sequence was found
in the canine PBMCs. DNA from porcine hepatocytes and PERV-
infected canine peripheral blood mononuclear cell (PBMCs) were
used as positive controls, and pure water was used as the negative
control. Ladder ranged from 100 to 600 bp.
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mice [20,21] and nude mice [22] after injection of por-
cine islet cells. Pseudotyping with murine endogenous
retroviruses has been shown to be the mechanism of
transmission [23,24]. It was found that dogs possess the
same huPAR-1 and muPAR gene sequence coding the
PERV receptors in humans, and were able to express
functional receptors for PERV, which implied that dogsFigure 3 Representative results of reverse transcriptase PCR
electrophoresis with the RNA extracted from the plasma. The
protease and polymerase gene were found only in circuit 3 before
and during treatment. C+, PK15 cells; C–, pure water. The ladder
ranged from 100 to 600 bp.might be infected by PERV through the same mechanism
as humans [25-27].
Reviewing the studies on the microbiological safety of
BALs, we found no evidence of crossspecies transmission
of PERV in patients treated with porcine BALs or living
pig tissue to date [18,28-37]. In previous studies, we did
not find any obvious enhanced PERV expression in
freshly isolated porcine hepatocytes by chitosan nanofi-
ber scaffold [38,39]. Although a number of studies have
investigated the possibility of PERV transmission, no
clear conclusion has been drawn. Therefore, viral secur-
ity is one of the most important issues that must be
resolved before our novel extracorporeal BAL system
can be used for clinical experiments.
PCR and RT-PCR are the most common methods used
to detect PERV transmission [12], and thus were used in
the present study. We assessed several pairs of primers
reported in previous publications [15,16,40], using them
in a number of PCR and RT-PCR assays with nucleic
acid extracted from canine cells. The three sets of pri-
mers finally used (protease, polymerase, and SsCytB)
were chosen because of their high specificity for PERV
detection in canine cells (data not shown), and the sensi-
tivity of PCR assays with these three primers has been
reported as 0.25 of a PK-15 cell per 104 cells [16], 0.3 of
a PK-15 cell per 105 cells [29], and 0.25 of a porcine cell
per 105 cells [16], respectively.
In the current study, PERV RNA, PERV DNA, and react-
ive RT were detected only in plasma samples taken during
circuit 3 of treatment. No activity was found in plasma dur-
ing circuits 1 or 2, or in PBMCs collected from the dogs.
All assays were negative for the porcine-specific SsCytB se-
quence. These results indicated that there was a possibility
of infectious PERV being in the system, but confined to cir-
cuit 3. For detection of microchimerism, we carried out
PCR with the porcine-specific SsCytB primers [16]. The
results were negative for PERV and SsCytB genes, suggest-
ing absence of microchimerism. Furthermore, negative RT
activity, consistent with the absence of PERV RNA in the
animal plasma, indicated no infection of the animals by
PERV, as RT activity is a generic marker for retroviruses
[41]. These results are similar to those of Kuddus et al.,
who reported that the RT activity and PERV RNA were lim-
ited to the shell of the bioreactor in their bio-artificial liver
support system (BLSS) [30]. In the plasma in circuit 3, we
found positive RT activity in all five samples before treat-
ment and in two of the five samples after 3 hours of treat-
ment, but in none of the five samples after 6 hours of
treatment. This eventual absence of RT activity may result
from the dilution effect of plasma on the reverse transcript-
ase or from an inhibiting effect of the animal plasma on the
RT activity.
An important part of our BAL system is the plasma com-
ponent separator, which uses semipermeable membranes of
Table 3 Reverse transcriptasde activity of the plasma at defined time intervals
Time point Beagle
1 2 3 4 5
Pre-treatment in circuit 3 Positive* Positive* Positive* Positive* Positive*
After 3 hours of treatment in circuit 3 Positive* Negative Negative Positive Negative
After 6 hours of treatment in circuit 3 Negative Negative Negative Negative Negative
Pre-treatment in circuit 2 Negative Negative Negative Negative Negative
After 3 hours of treatment in circuit 2 Negative Negative Negative Negative Negative
After 6 hours of treatment in circuit 2 Negative Negative Negative Negative Negative
Pre-treatment in circuit 1 Negative Negative Negative Negative Negative
After 3 hours of treatment in circuit 1 Negative Negative Negative Negative Negative
After 6 hours of treatment in circuit 1 Negative Negative Negative Negative Negative
Pre-treatment in circuit 1 Negative Negative Negative Negative Negative
3 hours after treatment Negative Negative Negative Negative Negative
12 hours after treatment Negative Negative Negative Negative Negative
24 hours after treatment Negative Negative Negative Negative Negative
3 days after treatment Negative Negative Negative Negative Negative
5 days after treatment Negative Negative Negative Negative Negative
7 days after treatment Negative Negative Negative Negative Negative
2 weeks after treatment Negative Negative Negative Negative Negative
1 month after treatment Negative Negative Negative Negative Negative
3 months after treatment Negative Negative Negative Negative Negative
6 months after treatment Negative Negative Negative Negative Negative
*Positive result.
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of the retrovirus [42]. Furthermore, the duration of blood
perfusion was just 6 hours, thus it is reasonable to infer that
the PERV DNA and RNA were removed by the filtration
from the collected plasma and PBMCs of the beagles in our
study, and thus that no PERV was transmitted across the
plasma component separator during the treatment phase.
We considered that the lack of PERV transmission in our
system is likely to be the result of a combination of no dir-
ect contact between the porcine hepatocytes and the dog
blood, the small pore size of the semipermeable mem-
branes in the plasma component separator, and the short
term of BAL treatment.
We also performed in vitro infection experiments to
assess the infectivity of PERV in our system and the in-
fection state of the dogs. Nyberg et al. [43] reported that
HEK293 cells could not be infected by the supernatant
of in vitro cultured porcine hepatocytes, and that human
plasma from patients with fulminant hepatic failure
would not affect its infectivity. In other trials, no
HEK293 cells were found to be infected in an in vitro in-
fection experiment of another two extracorporeal BAL
systems, the Academic Medical Center (AMC)-BAL and
the HepatAssist system [18,28]. Similarly, we found no
infection of HEK293 cells by PERV in our system.In conclusion, we found no evidence of PERV infection
in our dog model after treatment with our novel BAL
support system, suggesting that the system does not pose
a risk for PERV transmission. These results indicate that
the microbiological safety profile of the system should be
sufficient to allow clinical trials. However, BAL treatment
of patients would be a more complicated process. Fur-
ther studies into the microbiological safety of our BAL
system in clinical used need to be performed.
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